Real-world treatment attrition rates in advanced esophagogastric cancer

Table 1 Baseline characteristics of 245 patients with advanced esophagogastric cancer who received at least one line of systemic therapy

	Only one line of therapy (n = 122)	At least two lines of therapy (n = 123)	P value
Median age (IQR)	68 (61.7-73.7)	62 (56.1-70.6)	< 0.05
Gender, n (%)			0.37
Male	96 (79)	90 (73)
Female	26 (21)	33 (27)
Ethnicity, n (%)			0.59
Caucasian	101 (83)	95 (77)
Asian	15 (12)	21 (17)
East Asian	6 (5)	6 (5)
Other	0	1 (1)
Histology, n (%)			0.92
Adenocarcinoma	96 (79)	95 (77)
Squamous cell carcinoma	9 (7)	11 (9)
Signet ring cell	17 (14)	17 (14)
HER2 status, n (%)			0.41
Positive	27 (22)	37 (30)
Negative	70 (57)	72 (59)
Unknown	25 (20)	14 (11)
MMR status by IHC, n (%)			1.0
Deficient MMR	1 (1)	1 (1)
Proficient MMR	34 (28)	55 (45)
Unknown	87 (71)	67 (54)
Grade, n (%)			0.14
Well	3 (2)	5 (4)
Moderate	30 (25)	42 (34)
Poor	58 (48)	45 (37)
Unknown	31 (25)	31 (25)
Site of primary, n (%)			0.44
Gastric	44 (36)	46 (37)
GEJ/esophagus	78 (64)	77 (63)
Location of metastases, n (%)
Lymph node	64 (52)	54 (44)	0.20
Lung	29 (24)	28 (67)	0.88
Liver	39 (32)	50 (41)	0.18
Peritoneum	31 (25)	23 (19)	0.22
Other	28 (23)	16 (13)	0.05
Disease presentation, n (%)			0.89
De novo disease	87 (71)	89 (72)
Recurrent disease	35 (29)	34 (28)
Previous chemoradiation, n (%)	32 (26)	29 (24)	0.66
Previous resection, n (%)	27 (22)	24 (20)	0.64
ECOG at baseline, n (%)			0.14
0	11 (9)	20 (16)
1	83 (68)	84 (68)
2	28 (23)	19 (15)
Best response to first-line treatment, n (%)			< 0.05
Complete response	6 (5)	4 (3)
Partial response	33 (27)	46 (37)
Stable disease	20 (16)	38 (31)
Progressive disease	58 (48)	33 (27)
Unknown	5 (4)	2 (2)
Median duration of first-line treatment	2.7 (0.9-6.1)	5.00 (3.5-9.8)	< 0.05
Reason for discontinuation of first-line treatment, n (%)			0.02
Progression	82 (67)	101 (82)
Toxicity	15 (12)	4 (3)
Other	23 (19)	17 (14)
Unknown	2 (2)	1 (1)

IQR: Interquartile range; HER2: Human epidermal growth factor receptor 2; MMR: Mismatch repair; IHC: Immunohistochemistry; GEJ: Gastroesophageal junction.